Skip to main content
Clinical Trials/NCT06370949
NCT06370949
Not yet recruiting
Not Applicable

Comparison of the Effectiveness of Bupivacaine and Bupivacaine+Dexmedetomidine Combination in Transversus Abdominis Plane* Block in Colorectal Cancer Surgery

Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital1 site in 1 country84 target enrollmentMay 1, 2024

Overview

Phase
Not Applicable
Intervention
Bupivacain
Conditions
Colorectal Cancer
Sponsor
Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
Enrollment
84
Locations
1
Primary Endpoint
Analgesic effectiveness of bupivacain and bupivacain+dexmedetomidine combination in colorectal cancer surgery
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

Transversus abdominis plane (TAP) block is an anesthesia method that provides somatic analgesia to the anterior and lateral abdominal walls. Thus, TAP block is widely implemented in perioperative management of colorectal cancer patients.

Researchers aimed to evaluate the analgesic effectiveness and duration of effect of dexmedetomidine added to bupivacaine in the TAP block applied in colorectal cancer surgeries.

Detailed Description

Transversus abdominis plane (TAP) block is an anesthesia method that provides somatic analgesia to the anterior and lateral abdominal walls. With the increasing use of ultrasound guidance during peripheral nerve blocks, trunk blocks such as the transversus abdominis plane (TAP) block are widely used for analgesia after abdominal surgery. The advantages of TAP block include being less invasive than epidural analgesia, lower incidence of hypotension, and shorter hospital stay. Due to these advantages, TAP block has become a widely preferred method. Researchers aimed to evaluate the analgesic effectiveness and duration of effect of dexmedetomidine added to bupivacaine in the TAP block applied in colorectal cancer surgeries. The study will be conducted in a tertiary oncology hospital in Turkey and 84 colorectal cancer patients will be included.

Registry
clinicaltrials.gov
Start Date
May 1, 2024
End Date
November 30, 2024
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
Responsible Party
Principal Investigator
Principal Investigator

Beyza Seker

Resident Anaesthesiologist

Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital

Eligibility Criteria

Inclusion Criteria

  • colorectal cancer diagnosis
  • undergoing colorectal cancer surgery

Exclusion Criteria

  • allergic reaction to local anesthetics
  • bleeding anomalies
  • infection in TAP block area

Arms & Interventions

bupivacaine

Ultrasonography (USG) guided bilateral TAP block:20 ml %0,25 concentration bupivacain

Intervention: Bupivacain

bupivacaine+dexmedetomidine

Ultrasonography (USG) guided bilateral TAP block: 20 ml %0,25 concentration bupivacain+ 0.5 mcg/kg dexmedetomidine

Intervention: bupivacain+dexmedetomidine

Outcomes

Primary Outcomes

Analgesic effectiveness of bupivacain and bupivacain+dexmedetomidine combination in colorectal cancer surgery

Time Frame: postoperative day two

Numeric Rating Scales of two groups in postoperative period. The numeric rating scale (NRS) is a pain screening tool, commonly used to assess pain severity at that moment in time using a 0-10 scale, with zero meaning "no pain" and 10 meaning "the worst pain imaginable"

Study Sites (1)

Loading locations...

Similar Trials